Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Lifileucel |
Trade Name | Amtagvi |
Synonyms | LN-144|LN144|LN 144 |
Drug Descriptions |
Amtagvi (lifileucel) is a preparation of tumor-infiltrating lymphocytes isolated and expanded from patient tumor tissue, which may demonstrate enhanced anti-tumor immune activity when re-introduced into patients (PMID: 33979178). Amtagvi (lifileucel) is FDA-approved for use in patients with previously treated unresectable or metastatic melanoma (FDA.gov). |
DrugClasses | |
CAS Registry Number | 2306267-74-1 |
NCIT ID | C120552 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Aldesleukin + Lifileucel | Aldesleukin Lifileucel | 0 | 1 |
Cyclophosphamide + Fludarabine + Lifileucel + Pembrolizumab | Cyclophosphamide Fludarabine Lifileucel Pembrolizumab | 0 | 1 |
Lifileucel | Lifileucel | 0 | 7 |
Lifileucel + Pembrolizumab | Lifileucel Pembrolizumab | 0 | 2 |